Answers are grounded in this paper and cite their sources.
Background In women with diminished ovarian reserve (DOR), managing spontaneous luteinizing hormone (LH) elevation during antagonist-free ovarian stimulation presents a clinical dilemma, and the optimal post-elevation strategy remains unclear. We compared an integrated strategy combining rescue-antagonist avoidance with empirically scheduled early oocyte retrieval against rescue GnRH antagonist administration followed by fixed-time retrieval. Methods This multicenter retrospective cohort study included 936 unique-patient in vitro fertilization or intracytoplasmic sperm injection cycles from three reproductive medicine centers between January 2020 and January 2025. Eligible patients had DOR (AMH < 1.1 ng/mL and/or AFC < 7), underwent antagonist-free stimulation, and developed first documented spontaneous LH elevation ≥ 10 mIU/mL before planned retrieval; time zero (T0) was defined as the first detection of LH ≥ 10 mIU/mL. In both strategies, hCG for final oocyte maturation was administered on the day of T0 once the post-LH-elevation strategy had been selected. In the rescue-antagonist control strategy, cetrorelix 0.25 mg was administered subcutaneously daily from T0 until hCG, and retrieval was scheduled at approximately 36 h after hCG. In the integrated strategy, rescue antagonist was withheld; E2 was remeasured the day after hCG, and retrieval was scheduled at approximately 26, 29, or 35 h after hCG according to prespecified empirical E2-decline categories (> 50%, 33%–50%, and < 33%). The primary outcome was the number of metaphase II (MII) oocytes; the key secondary outcome was retrieval of at least one MII oocyte. Inverse probability of treatment weighting (IPTW) was used to adjust for measured confounders. Results In the primary complete-case IPTW analysis of 916 cycles, the integrated strategy was associated with a higher MII oocyte count (incidence rate ratio 1.51, 95% confidence interval 1.25–1.82; P < 0.001) and higher odds of MII-positive retrieval (odds ratio 1.82, 95% confidence interval 1.21–2.74; P = 0.003). IPTW-standardized probabilities of retrieving at least one MII oocyte were 74.5% in the integrated group and 60.2% in the control group, an absolute difference of 14.3% points. Results were directionally consistent in sensitivity and per-protocol analyses. Pregnancy and live birth proportions among cycles reaching embryo transfer were similar between groups and are reported only as exploratory post-treatment outcomes. Conclusions An integrated strategy of rescue-antagonist avoidance and empirically timed early retrieval was associated with a higher MII oocyte yield and a greater probability of obtaining at least one MII oocyte than rescue antagonist followed by fixed-time retrieval. These observational findings support the comparative effectiveness of a composite care bundle rather than a specific endocrine mechanism or a validated E2-based timing algorithm. Prospective external validation is required.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: